JPRN-UMIN000008236已完成未知
Phase II study evaluating safety and efficacy of maintenance therapy with bortezomib, lenalidomide and dexamethasone for multiple myeloma - SMUIM4-MM01
Fourth Department of Internal Medicine, Sapporo Medical University Hospital0 个研究点目标入组 30 人开始时间: 2012年6月22日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 80years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. Non-secretory MM and plasmacell leukemia. 2. Patients HIV-HBs-and HCV-positive 3. Severe hepatic dysfunction, severe renal failure, severe cardiac dysfunction, severe pulmonary dysfunction, uncontrolled diabetes, uncontrolled hypertension, and uncontrolled infection. 4. Patients with a history of active malignancy during the past 5 years. 5. Patients with psychiatric disorders such as schizophrenia etc. 6. History of hypersensitivity to mannitol or boron. 7. Patient was suspected pneumonia(Interstitial pneumonia). Consult a respiratory specialist if necessary 8. Those who are considered as inappropriate to register by attending physicians.
研究者
相似试验
未知
2 期
Phase 2 Study of MR13A9.JPRN-jRCT2080223210Maruishi Pharmaceutical Co., Ltd.100
已完成
2 期
Phase II trial evaluating safety and efficacy of ME2136 combined with standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based highly emetogenic chemotherapySolid cancerJPRN-jRCT2041200071Yasui Hirofumi40
进行中（未招募）
1 期
Study to assess efficacy and safety of the medication named Idarubicin given orally every other day to patients with advanced tumor of the liver who progressed or are intoelrant to the medication Sorafenib and RegorafenibPatients with interemdiate-advanced stage hepatocarcinomaMedDRA version: 21.0Level: LLTClassification code 10024662Term: Liver cell carcinoma non-resectableSystem Organ Class: 100000004864EUCTR2017-003653-42-ITCENTRO DI RIFERIMENTO ONCOLOGICO47
已完成
2 期
Phase II study assessing the efficacy and safety of lenvatinib for anaplastic thyroid cancer (HOPE)JPRN-UMIN000020773Translational Research Informatics Center, Foundation for Biomedical Research and Innovation39
已完成
不适用
Phase II study evaluating safety and efficacy of induction therapy with small-dose bortezomib, lenalidomide and dexamethasone combination for previously untreated symptomatic multiple myelomaMultiple MyelomaJPRN-UMIN000016265Sapporo Medical University Hospital30